Member States have once again crossed swords on EU pharmaceutical policy. At the Health Council on Monday 9 December, the large Member States, who are able to negotiate with pharmaceutical companies, and the smaller ones, who have more difficulty in having their interests respected, presented different views on the need to work together.
Not surprisingly, a large majority of States have indicated that they are more frequently facing shortages of increasingly expensive medicines, as...